期刊
MABS
卷 9, 期 4, 页码 615-627出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/19420862.2017.1290752
关键词
Antibody Drug Conjugate (ADC); breast cancer; CD175s; colon cancer; ovarian cancer; sialyl-Tn; STn; Tumor-Associated Carbohydrate Antigen (TACA)
资金
- National Cancer Institute (NCI) of the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) [1R43CA186326-01A1, HHSN261200700063C, HHSN261200900034C]
- NATIONAL CANCER INSTITUTE [R43CA186326] Funding Source: NIH RePORTER
Targeted therapeutics that can differentiate between normal and malignant tumor cells represent the ideal standard for the development of a successful anti-cancer strategy. The Sialyl-Thomsen-nouveau antigen (STn or Sialyl-Tn, also known as CD175s) is rarely seen in normal adult tissues, but it is abundantly expressed in many types of human epithelial cancers. We have identified novel antibodies that specifically target with high affinity the STn glycan independent of its carrier protein, affording the potential to recognize a wider array of cancer-specific sialylated proteins. A panel of murine monoclonal anti-STn therapeutic antibodies were generated and their binding specificity and efficacy were characterized in vitro and in in vivo murine cancer models. A subset of these antibodies were conjugated to monomethyl auristatin E (MMAE) to generate antibody-drug conjugates (ADCs). These ADCs demonstrated in vitro efficacy in STn-expressing cell lines and significant tumor growth inhibition in STn-expressing tumor xenograft cancer models with no evidence of overt toxicity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据